Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com

ONC201 Publications

onc201

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

J Immunother Cancer. 2019 PMID: 31118108

Stein MN, Malhotra J, Tarapore RS, et al.

onc201

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

Clin Cancer Res. 2019 PMID: 30559168

Prabhu VV, Madhukar NS, Gilvary C, et al.

onc201

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

J Clin Invest. 2018 PMID: 29533922

Wagner J, Kline CL, Zhou L, et al.

onc201

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget

Oncotarget. 2017 PMID: 29108308

Arrillaga-Romany I, Chi AS, Allen JE, et al.

onc201

First-in-Human clinical trial of oral ONC201 in patients with refractory solid tumors

Clin Cancer Res. 2017 PMID: 28331050

Stein MN, Bertino JR, Kaufman HL, et al.

onc201

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Sci Signal. 2016 PMID: 26884599

Ishizawa J, Kojima K, Chachad D, et al.

onc201

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

Sci Signal. 2016 PMID: 26884600

Kline CLB, Van den Heuvel APJ, Allen JE, et al.

onc201

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

Science Translational Medicine 2013, PMID: 23390247

Allen JE, Krigsfeld G, Mayes PA, et al.

« Previous 1 2